Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 2, 1996, Pages 138-144

  Marinac, Jacqueline S ^a   Balian, John D ^b   Foxworth, John W ^b   Willsie, Sandra K ^b   Daus, Jennifer C ^b   Owen, Renius ^b   Flockhart, David A ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; OMEPRAZOLE;

ADULT; ARTICLE; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; NEGRO; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; WESTERN HEMISPHERE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PHENOTYPE; REFERENCE VALUES;

EID: 0029912595     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90129-0     Document Type: Article

References (45)

1. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. S-Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984;36:773-80.
2. Alvan G. Clinical consequences of polymorphic drug oxidation. Fundam Clin Pharmacol 1991;5:209-28.
3. Küpfer A, Preisig R. Pharmacogenetics of S-mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984;26:753-9.
4. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
5. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16:183-7.
6. Flockhart DA, Clauw DJ, Sale EB, Hewett J, Woosley RL. Pharmacogenetic characteristics of eosinophiliamyalgia syndrome. Clin Pharmacol Ther 1994;56:398-405.
7. May DG, Black CM, Olsen NJ, Csuka ME, Tanner SB, Bellino L, et al. Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and S-mephenytoin. Clin Pharmacol Ther 1990;48:286-95.
8. Kaisary A, Smith P, Jacqz E, McAllister CB, Wilkinson GR, Ray WA, et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and S-mephenytoin as risk factors. Cancer Res 1987; 47:5488-93.
9. Cartwright RA, Philip PA, Rogers HJ, Glashan RW. Genetically determined debrisoquine oxidation capacity in bladder cancer. Carcinogenesis 1984;5: 1191-2.
10. May DG. Genetic differences in drug disposition. J Clin Pharmacol 1994;34:881-97.
11. Wrighton SA, Stevens JC, Becker GW, Vandenbranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993;306:240-5.
12. Goldstein JA, Faletto MB, Romke-Sparks M, Sullivan T, Kitareewan S, Raucy JL, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33:1743-52.
13. Setiabudy R, Chiba K, Kusuka M, Ishizaki T. Caution in the use of 100 mg of racemic S-mephenytoin for phenotyping Southeastern Oriental subjects. Br J Clin Pharmacol 1992;33:665-6.
14. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al. The hydroxylation of omeprazole correlates with 5-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995;57:662-9.
15. Wilkinson GR, Guengrich PF, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76.
16. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, et al. Interethnic differences in genetic polymorphism of debrisoquine and S-mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-8.
17. Pollock BG, Perel JM, Kirshner M, Altieri LP, Yeager AL, Reynnolds CF. S-Mephenytoin 4-hydroxylation in older Americans. Eur J Clin Pharmacol 1991;40:609-11.
18. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995;57:656-61.
19. Iyun AO, Tucker GT, Woods HF, Lennard MS. The 4-hydroxylation of S-mephenytoin in Nigerians: a population study. In: Ingelman-Sundberg M, Gustafsson JA, Orrenius S, editors. Presented at the Eighth International Symposium on Microsomes and Drug Oxidations, Stockholm, 1990.
20. Flockhart DA. Drug interactions and the cytochrome P450 system. Clin Pharmacokinet 1995;29:45-52.
21. Skjelbo E, Gram LF, Brøsen K. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio): a population study. Br J Clin Pharmacol 1993;35:331-4.
22. Skjelbo E, Brøsen K, Hallas J, Gram LF. The S-mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Br J Clin Pharmacol 1993;35:331-4.
23. Nielsen KK, Brøsen K, Jeppe Hansen MG, Gram LF. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994;55:518-27.
24. Breyer-Pfaff U, Pfandl B, Nill K, Nusser E, Monney C, Jonzier-Perey M, et al. Enantioselective amitripty-line metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther 1992;52: 350-8.
25. Jacqz E, Hall SD, Branch RA, Wilkinson GR. Polymorphic metabolism of S-mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital. Clin Pharmacol Ther 1986;39:646-53.
26. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villen T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1989;45:348-55.
27. Helsby NA, Ward SA, Howells RE, Breckenridge AM. In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the S-mephenytoin hydroxylase (P450MP) enzyme. Br J Clin Pharmacol 1990;30:287-91.
28. Ward SA, Helsby NA, Skjelbo K, Brøsen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the S-mephenytoin oxidation polymorphism. Br J Clin Pharmacol 1991;31:689-92.
29. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both S-mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989;45:7279.
30. Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12:415-6.
31. Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992;2:25-31.
32. Gram LF, Guentert TW, Grange S, Vistisen K, Brøsen K. Moclobemide: a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6 and CYP1A2: a panel study. Clin Pharmacol Ther 1995;57:670-7.
33. Curi-Pedrosa R, Pichard L, Bonfils C, Jacqz-Algrain E, Maurel P. Major implication of cytochrome P450 3A4 in the oxidative metabolism of the antisecretory drugs omeprazole and lansoprazole in human liver microsomes and hepatocytes [abstract]. Br J Clin Pharmacol 1993;36:156P.
34. Lagerstrom PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 1984;309:347-56.
35. Regårdh CG. Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol Suppl 1986;118:99-104.
36. Snedecor CW, Cochrane WG. Normal distribution: statistical methods. 7th ed. Ames Iowa: Iowa State University Press, 1980.
37. Zar JH. Biostatistical analysis. 2nd ed. Englewood Cliffs, NJ: Prentice-Hall, 1984:378.
38. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
39. Brøsen K, deMorais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995;5:312-7.
40. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an oriental population. J Pharmacol Exp Ther 1992;262: 1195-202.
41. Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, et al. Interphenotype differences in disposition and effect of gastrin levels of omeprazole: suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995;39:511-8.
42. Chang M, Dahl M, Tybring G, Götharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995;5: 358-63.
43. Vinayek R, Amantea MA, Maton PN, Grucht H, Gardner JD, Kensen RT. Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. Gastroenterology 1991; 101:138-47.
44. Lanzon-Miller S, Pounder RE, Hamilton MR, Ball S, Chronos NA, Raymond F, et al. Twenty-four hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1987;1:239-51.
45. Wright JM, Sarich TC. Omeprazole therapy in resistant reflux disease [letter]. Ann Intern Med 1995;122: 236.